Olga Salamero

2.8k total citations
46 papers, 890 citations indexed

About

Olga Salamero is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Olga Salamero has authored 46 papers receiving a total of 890 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hematology, 18 papers in Genetics and 16 papers in Molecular Biology. Recurrent topics in Olga Salamero's work include Acute Myeloid Leukemia Research (30 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Histone Deacetylase Inhibitors Research (9 papers). Olga Salamero is often cited by papers focused on Acute Myeloid Leukemia Research (30 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Histone Deacetylase Inhibitors Research (9 papers). Olga Salamero collaborates with scholars based in Spain, United States and United Kingdom. Olga Salamero's co-authors include Francesc Bosch, Jorge Sierra, Emili Montserrat, Jordi Esteve, Josep Nomdedéu, Lourdes Escoda, Montserrat Hoyos, Pau Montesinos, Josep‐María Ribera and Salut Brunet and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Olga Salamero

43 papers receiving 878 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Olga Salamero Spain 13 625 381 282 180 167 46 890
Paulo Lúcio Portugal 13 469 0.8× 255 0.7× 181 0.6× 308 1.7× 160 1.0× 30 854
Susana Vives Spain 10 533 0.9× 272 0.7× 152 0.5× 231 1.3× 209 1.3× 37 791
Yue‐Yun Lai China 14 542 0.9× 196 0.5× 256 0.9× 159 0.9× 119 0.7× 79 693
Deborah Fuchs United States 8 606 1.0× 368 1.0× 310 1.1× 62 0.3× 101 0.6× 20 882
Joseph O. Moore United States 10 1.0k 1.7× 555 1.5× 368 1.3× 350 1.9× 181 1.1× 17 1.3k
Valentina Gianfelici Italy 15 312 0.5× 243 0.6× 133 0.5× 280 1.6× 168 1.0× 29 736
C. Michel Zwaan Netherlands 17 689 1.1× 349 0.9× 186 0.7× 323 1.8× 167 1.0× 36 992
Ruth Heaton United States 5 684 1.1× 337 0.9× 284 1.0× 72 0.4× 108 0.6× 8 847
T. Karakas Germany 11 346 0.6× 478 1.3× 122 0.4× 200 1.1× 220 1.3× 15 858
Kiyotaka Kashima Japan 8 992 1.6× 499 1.3× 386 1.4× 274 1.5× 132 0.8× 14 1.2k

Countries citing papers authored by Olga Salamero

Since Specialization
Citations

This map shows the geographic impact of Olga Salamero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olga Salamero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olga Salamero more than expected).

Fields of papers citing papers by Olga Salamero

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olga Salamero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olga Salamero. The network helps show where Olga Salamero may publish in the future.

Co-authorship network of co-authors of Olga Salamero

This figure shows the co-authorship network connecting the top 25 collaborators of Olga Salamero. A scholar is included among the top collaborators of Olga Salamero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olga Salamero. Olga Salamero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pratcorona, Marta, Ana Garrido, Álex Bataller, et al.. (2023). Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort. Blood Cancer Journal. 13(1). 69–69. 9 indexed citations
2.
Boyiadzis, Michael, Pinkal Desai, William B. Donnellan, et al.. (2022). First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia. Clinical and Translational Science. 16(3). 429–435. 18 indexed citations
3.
Bataller, Álex, Ana Garrido, Montserrat Hoyos, et al.. (2021). Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Advances. 6(3). 882–890. 19 indexed citations
4.
Fox, María Laura, Irene García‐Cadenas, Ariadna Pérez, et al.. (2020). Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. Leukemia & lymphoma. 61(8). 1823–1832. 2 indexed citations
5.
Salamero, Olga, Pau Montesinos, Christophe Willekens, et al.. (2020). First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology. 38(36). 4260–4273. 73 indexed citations
6.
7.
Ortí, Guillermo, Jaime Sanz, Irene García‐Cadenas, et al.. (2018). Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. Experimental Hematology. 62. 24–32. 9 indexed citations
8.
9.
Pomares, Helena, Guillermo Villacampa, Esther Alonso, et al.. (2018). Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes. Leukemia & lymphoma. 60(6). 1522–1527. 1 indexed citations
10.
Ortí, Guillermo, Pere Barba, María Laura Fox, et al.. (2016). Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect. Experimental Hematology. 48. 1–11. 49 indexed citations
11.
Vallejo, Carlos, Pau Montesinos, Marta Polo, et al.. (2015). Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis. Annals of Hematology. 94(6). 947–954. 25 indexed citations
12.
Díaz‐Beyá, Marina, Alfons Navarro, Salut Brunet, et al.. (2014). The LincRNA HOTAIRM1, Located in the HOXA genomic Region, impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature. Blood. 124(21). 1003–1003. 1 indexed citations
13.
Knapper, Steven, Timothy Chevassut, Rafael F. Duarte, et al.. (2013). Elacytarabine in relapsed/refractory acute myeloid leukaemia: An evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile. Leukemia Research. 38(3). 346–351. 2 indexed citations
14.
Giraldo, Pilar, Pilar Alfonso, Pilar Irún, et al.. (2013). Substrate Reduction Therapy With Miglustat In Type 1 Gaucher Disease In Spain. Nine Years Outcomes Update On ZAGAL Study. Blood. 122(21). 4713–4713. 4 indexed citations
15.
Baptista, Maria João, Ana Muntañola, Pau Abrisqueta, et al.. (2012). Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status. Clinical Cancer Research. 18(21). 5924–5933. 4 indexed citations
16.
Nomdedéu, Josep, Montserrat Hoyos, Jordi Esteve, et al.. (2012). Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group. Leukemia Research. 36(8). 990–997. 32 indexed citations
17.
Bosch, Francesc, Pau Abrisqueta, Neus Villamor, et al.. (2008). Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) Is a Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia.. Blood. 112(11). 2097–2097. 7 indexed citations
18.
Rosiñol, Laura, et al.. (2006). Bortezomib: an effective agent in extramedullary disease in multiple myeloma. European Journal Of Haematology. 76(5). 405–408. 89 indexed citations
19.
Cibeira, María Teresa, et al.. (2006). Bortezomib-Induced Rhabdomyolysis in Multiple Myeloma. Acta Haematologica. 116(3). 203–206. 3 indexed citations
20.
Mercadal, Santiago, Antonio Martı́nez, Benet Nomdedeu, et al.. (2006). Herpes simplex and Epstein‐Barr virus lymphadenitis in a patient with chronic lymphocytic leukemia treated with fludarabine. European Journal Of Haematology. 77(5). 442–444. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paulo Lúcio Breakdown of academic impact, for papers by Susana Vives Breakdown of academic impact, for papers by Yue‐Yun Lai Breakdown of academic impact, for papers by Deborah Fuchs Breakdown of academic impact, for papers by Joseph O. Moore Breakdown of academic impact, for papers by Valentina Gianfelici Breakdown of academic impact, for papers by C. Michel Zwaan Breakdown of academic impact, for papers by Ruth Heaton Breakdown of academic impact, for papers by T. Karakas Breakdown of academic impact, for papers by Kiyotaka Kashima
Rankless by CCL
2026